Participants randomized to the experimental arm will continue with standard of care treatment but will also undergo radiation simulation for L-SABR/Liver Stereotactic Ablative Radiation Therapy.
L-SABR will be delivered in a week during which the patient receives no chemotherapy. L-SABR can be on the same week or even day as anti-PD-(L)1 therapy.
Other Name: Liver Stereotactic Ablative Radiation Therapy
Biological: Anti-PD-(L)1 based immunotherapy
Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
Other Name: Standard of Care
Drug: Platinum based chemotherapy
Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
Other Name: Standard of Care
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
